Literature DB >> 12325077

A PLP splicing abnormality is associated with an unusual presentation of PMD.

Grace M Hobson1, Zhong Huang, Karen Sperle, Deborah L Stabley, Harold G Marks, Franca Cambi.   

Abstract

We report that a deletion of 19 base pairs (bp) in intron 3 of the proteolipid protein (PLP/DM20) gene causes a neurological disease characterized by mild developmental delay, followed by progressive decline of acquired motor and cognitive milestones. The clinical features are associated with mild delay in myelination demonstrated by magnetic resonance imaging studies and with ongoing demyelination and axonal loss demonstrated by magnetic resonance spectroscopy. We demonstrate that the purine-rich 19bp element regulates PLP-specific splice site selection in transient transfections of chimeric constructs into cultured oligodendrocytes. Runs of 4 and 5 Gs centered in the 19bp element are critical for efficient PLP-specific splicing. The intronic element is sequence specific in oligodendrocytes and is not a repressor of PLP-specific splicing in nonglial cells. These data support the conclusion that deletion of the 19bp purine-rich region in PLP intron 3 causes a reduction in PLP message and protein, which affects myelin stability and axonal integrity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12325077     DOI: 10.1002/ana.10320

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  22 in total

1.  The QKI-PLP pathway controls SIRT2 abundance in CNS myelin.

Authors:  H Zhu; L Zhao; E Wang; N Dimova; G Liu; Y Feng; F Cambi
Journal:  Glia       Date:  2011-09-21       Impact factor: 7.452

2.  G Run-mediated recognition of proteolipid protein and DM20 5' splice sites by U1 small nuclear RNA is regulated by context and proximity to the splice site.

Authors:  Erming Wang; William F Mueller; Klemens J Hertel; Franca Cambi
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

3.  MicroRNA expression in mouse oligodendrocytes and regulation of proteolipid protein gene expression.

Authors:  Erming Wang; Franca Cambi
Journal:  J Neurosci Res       Date:  2012-04-14       Impact factor: 4.164

4.  Frameshift mutation in GJA12 leading to nystagmus, spastic ataxia and CNS dys-/demyelination.

Authors:  Nicole I Wolf; Maria Cundall; Paul Rutland; Elisabeth Rosser; Robert Surtees; Sarah Benton; Wui K Chong; Sue Malcolm; Friedrich Ebinger; Maria Bitner-Glindzicz; Karen J Woodward
Journal:  Neurogenetics       Date:  2006-09-13       Impact factor: 2.660

Review 5.  PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2.

Authors:  Ken Inoue
Journal:  Neurogenetics       Date:  2004-12-31       Impact factor: 2.660

6.  Sex chromosome complement influences functional callosal myelination.

Authors:  S Moore; R Patel; G Hannsun; J Yang; S K Tiwari-Woodruff
Journal:  Neuroscience       Date:  2013-04-15       Impact factor: 3.590

7.  Proton MR spectroscopic imaging in Pelizaeus-Merzbacher disease.

Authors:  Francesca Pizzini; Ali S Fatemi; Peter B Barker; Lidia M Nagae-Poetscher; Alena Horská; Andrew W Zimmerman; Hugo W Moser; Genila Bibat; Sakkubai Naidu
Journal:  AJNR Am J Neuroradiol       Date:  2003-09       Impact factor: 3.825

8.  PMD patient mutations reveal a long-distance intronic interaction that regulates PLP1/DM20 alternative splicing.

Authors:  Jennifer R Taube; Karen Sperle; Linda Banser; Pavel Seeman; Barbra Charina V Cavan; James Y Garbern; Grace M Hobson
Journal:  Hum Mol Genet       Date:  2014-06-01       Impact factor: 6.150

9.  Novel pathologic findings in patients with Pelizaeus-Merzbacher disease.

Authors:  Jeremy J Laukka; John Kamholz; Denise Bessert; Robert P Skoff
Journal:  Neurosci Lett       Date:  2016-05-17       Impact factor: 3.046

10.  Heterogeneous nuclear ribonucleoproteins H and F regulate the proteolipid protein/DM20 ratio by recruiting U1 small nuclear ribonucleoprotein through a complex array of G runs.

Authors:  Erming Wang; Franca Cambi
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.